Effect of mushrooms on obesity in animal models: study protocol for a systematic review and meta-analysis

Denise Grotto*, Isabella Ferreira Camargo, Katia Kodaira, Lauren Giustti Mazzei, Juliana Castro, Raquel Andrade Leite Vieira, Cristiane de Cássia Bergamaschi and Luciane Cruz Lopes

Abstract

Background: Obesity and its consequences are worldwide epidemic problem; therefore, studies with strategies and mechanisms that favor weight loss to improve outcomes in health are necessary. Effects of mushrooms on body weight are uncertain. The aim of this systematic review is to determine the efficacy of mushrooms in weight loss in animal preclinical models.

Method: This is a systematic review of preclinical studies of animal models of obesity (any type of non-aquatic mammal), which were exposed to edible and medicinal mushrooms orally in comparison with the control. The following databases will be used: MEDLINE (PubMed), Web of Science, BIOSIS, SCOPUS, and gray literature. There will be no restriction of language, date, or publication status. The primary outcome will be body weight loss. And the secondary outcomes include the total amount of food consumed by the animals, analysis of metabolic parameters, inflammatory mediators, mortality for any causes, and any adverse effect reported. A team of reviewers will select, in pairs and independently, the titles and abstracts, extract data from qualifying studies, and assess bias risk (using SYstematic Review Centre for Laboratory animal Experimentation SYRCLE’s risk of bias tool and the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) checklist). The standardized mean difference (SMD) will be calculated to measure treatment effect, with 95% confidence intervals (95% CI). The heterogeneity between-study will be calculated by $I^2$ inconsistency values and Cochran’s Q statistical test, where $I^2 > 50\%$ and/or $p < 0.10$ suggest high heterogeneity meta-analyses of random effects will be conducted as possible.

Discussion: Although many experimental studies about the effects of mushrooms on obesity have already been published, there is still no consensus in the literature. This study will provide evidences of preclinical research on mushrooms and their relation to body weight loss in animal models of obesity, being non-aquatic mammals. Also, this systematic review will show the limitations and strengths of the studies available in the literature, as well as it will to encourage the financing of new studies by public health managers and governmental entities.

Systematic review registration: PROSPERO (CRD42019125299).

Keywords: Obesity, Mushroom, Body weight loss, Animal experimentation, Study protocol, Systematic review

* Correspondence: denise.grotto@prof.uniso.br
Pharmaceutical Sciences Graduate Course, University of Sorocaba, Rodovia Raposo Tavares, Km 92.5, Sorocaba, SP 18023-000, Brazil

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Obesity is defined as excessive accumulation of fat in adipose tissue; a consequence of imbalance involving intake, energy expenditure, and physical activity patterns [1, 2]. Drastic changes in social and eating habits have significantly impacted in health and nutritional status of individuals [3, 4].

The World Health Organization (WHO) considers obesity as one of the most obvious and neglected public health problems that threaten the present days [1]. The prevalence of obesity in the world population shows us a significant and accelerated growth of the disease in the last decades. Obesity has become a global epidemic, affecting not only developed but also developing countries and among all segments of society [5].

Besides being considered as a chronic disease, obesity is an important risk factor to no communicable chronic diseases such as diabetes, cardiovascular diseases, cancer, apnea, and osteoarthritis. The health consequences are numerous, such as the risk of premature death, debilitating complaints that affect the quality of life, and psychosocial disorders [1, 6, 7].

Obesity is increasingly considered a priority for human health and its treatment is essential due to its devastating effect on health as well as problems related to co-morbidities [8]. Lifestyle changes are the first choice to start treating obesity. Anti-obesity medications should be started when the behavioral change fails. Adverse effects of medication and potential for drug abuse are the main limitations to the indication of this therapy. Therefore, the search for alternative therapies for the treatment of obesity has increased considerably in the scientific environment [8–10].

Mushrooms have been used as foodstuff and folk medicine for thousands of years because of their nutritional and medical properties. Edible mushrooms, especially in the order Agaricales, have low calorie, low fat concentration, and high protein and fiber content, and they have the essential amino acids [11, 12]. Besides being a source of vitamins and minerals, edible mushrooms also have several biologically functional compounds, such as polysaccharides, glycoproteins, and antioxidants, which have been used mainly as antitumor and immunostimulant [11, 13, 14]. Likewise, medicinal mushrooms also have different functional compounds, with similar activities than edible mushrooms; antibacterial, hepatoprotective, anti-inflammatory, antitumor, and antioxidant action [15]. However, many studies have reported other beneficial from these mushrooms, as the anti-obesity, anti-diabetic, and anti-hyperlipidemic effects [16–22].

Iñiguez and colleagues reported that supplementation with Agaricus bisporus prevented excessive body weight gain and liver steatosis induced by high-fat-diet feeding. In the same way, dietary Sparassis crispa exhibited anti-obesity effect in rats with diet-induced obesity [17]. On the other hand, oral administration Lentinula edodes for 30 days was not sufficient to reduce body weight in a high-fat-diet feeding group [18]. Thus, although edible and medicinal mushrooms have been shown anti-obesity effects in numerous preclinical studies, the results are far from conclusive.

To our knowledge, no systematic review or meta-analysis has been reported critical evidence regarding the effects of mushrooms in animal models of obesity. Therefore, a systemic review and, if possible, a meta-analysis is proposed in order to assess the anti-obesity effects of edible and medicinal mushrooms in animal models of obesity.

Research question

What are the effects of edible and medicine mushrooms on the body weight loss in animal models of obesity?

Methods/design

This protocol was delineated according to the recommendations from the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols (PRISMA-P) [23] and the recommendations for reporting of systematic reviews and meta-analyses of animal experiments [24, 25]. The protocol was registered on International Prospective Register of Systematic Reviews (PROSPERO—CRD42019125299) (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=125299).

Eligibility criteria

Types of studies

The systematic review will include controlled studies (randomized and non-randomized), which evaluated the effect of edible and medicinal mushrooms on preclinical animal models of obesity. Both unpublished and published studies are eligible for inclusion. There is no restriction of language, date, or publication status.

Types of animal models

We will include studies that used any type of non-aquatic mammals’ model, which have developed obesity genetically, physiological, through dietary, surgical, or seasonal obesity. Each of these models mimics at least part of the various pathophysiological aspects of obesity.

Types of comparators

The comparison group will include animals whose obesity was preclinically induced but have not undergone any intervention.

Types of intervention

The intervention group will include animals that received edible or medicinal mushrooms to investigate
body weight loss. Although there are different types of mushrooms, only studies with edible or medicinal mushrooms will be accepted. We will select studies that have used the body of the mushroom (fruit body), powder formulations, or extracts of the mushrooms. To be included in our analysis, mushrooms must have been administered during or after the induction of experimental obesity.

Exclusion criteria
For this systematic review, in vitro experiments, case report studies, cohort studies, abstracts of congress, letters to the editor, and all human studies will be excluded. Studies comparing animal models of obesity with healthy animals and mushroom administration by other routes, such as intravenous, intramuscular, dermal, intradermal, and intraperitoneal routes, will also be excluded.

Exclusion criteria still comprise studies using edible or medicinal mushrooms as pre-treatment, studies using substances isolated from mushrooms and co-intervention studies, because of the risk of contamination. Moreover, hallucinogenic, poisonous, and toxic mushrooms will not be included in the systematic review.

Types of outcome measures
Primary
Primary outcome measures will be loss in body weight, assessed through body weight, and measured at the highest follow-up time following administration of the intervention.

Secondary
Secondary outcomes include the total amount of food consumed by the animals; analysis of metabolic parameters, such as total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, glycaemia, inflammatory mediators (interleukin-1 and tumor necrosis factor), mortality for any causes, and any adverse event reported by the authors in any time after mushroom administration.

Search methods for identification of studies
Electronic searches
The following electronic databases will be used: MEDLINE (PubMed); Web of Science, BIOSIS, SCOPUS, Google Scholar from its inception until November 2019. There will be no restriction of language, publication date, or publication status. We will also use Search Filter for laboratory animals, restricting for in vivo studies with non-aquatic mammals. Details of the PubMed search strategy appear in Additional file 1.

Data collection and analysis
Selection of studies
Pairs of reviewers (DG and KK, IFC and JC, RALV and CCB), independently, will screen titles and abstracts. Duplicates will be removed during the screening. Disagreements between researchers will be resolved by consensus or third review (LCL). After, same reviewers, in pairs and independently, will evaluate the full text of studies using a standardized form with included and excluded criteria. In case of duplicate publication, we will use the article with more complete data.

Data extraction
The same reviewers, working in pairs, will independently extract the data and will record information: (i) study design (number and type of studies—controlled trials randomized or non-randomized, unpublished and published studies), (ii) study characteristics (author, year of publication, study title), (iii) characteristics of the included animals and animal model (animal species, obesity model, age, gender, husbandry conditions, number of animals in intervention, and comparator group), (iv) interventions (animals that received edible or medicinal mushrooms, time and description of preparation, route given), (v) outcomes of interest (body weight, total amount food consumed, metabolic parameters and inflammatory mediators, death, adverse event). Before starting data abstraction, we will conduct calibration exercises to ensure consistency between reviewers.

Assessment of risk of bias and quality assessment in included studies
Methodological quality of the included studies will be assessed according to the SYstematic Review Centre for
Laboratory animal experimentation SYRCLE’s risk of bias tool [27] and the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (CAMARADES) checklist that evaluate the following: publication in a peer-reviewed journal, statement of control of temperature, randomized treatment allocation, blinded assessment of outcome, reporting of blinding of the operator, appropriate animal model, reporting of a sample size calculation, compliance with animal welfare regulations, statement of potential conflict of interest, and complete follow-up [28, 29].

**Measures of treatment effect**

Any type of continuous or dichotomous data will be collected. We will calculate standardized mean difference (SMD), odds ratio (OR), and related 95% confidence interval (95% CI) for each outcome using Cohen’s method to normalize the different animal species.

Dichotomous data will be calculated as risk ratio (RR) with 95% CI.

**Assessment of heterogeneity and data synthesis**

To determine whether the included studies have enough homogeneity for meta-analyses, we will estimate between-study heterogeneity by calculating $I^2$ inconsistency values and Cochran’s $Q$ statistical test, where $I^2 > 50\%$ and/or $p < 0.10$ suggest high heterogeneity. Heterogeneity will be defined according to the $I^2$ range: 0 to 40% indicated no important heterogeneity, 40 to 60% moderate heterogeneity, 60 to 90% substantial heterogeneity, and > 90% indicating considerable heterogeneity [30].

The meta-analyses of random effects will be conducted, by each outcome, when there are at least two studies. Data analysis will be performed by STATA® Statistical software version 14.2 (Stata Corp, College Station, USA). If quantitative synthesis is not appropriate, we will construct summary tables and provide a narrative synthesis.

**Grading the quality of evidence**

GRADE method will be used to interpret the results [31, 32]. The quality of evidence of the studies will be graded at four levels: very low, low, moderate, and high, based on risk of bias, inconsistency, indirectness, imprecision, and publication bias. Quality ratings will be made separately for each outcome. Based on study limitations, authors will make an overall judgment whether the quality of evidence for an outcome warrants downgrading. As GRADE’s indirectness domain is only applicable to human subjects, we will downgrade the quality of evidence by 1 (as serious indirectness). Also, the quality rating will be downgraded to level 1 if the evidence is classified as “serious” and to two levels if it is classified as “very serious.” However, it potential limitations will not be likely to lower confidence in the effect estimate, the evidence will not be downgraded.

**Assessment of publication bias**

A graphical funnel plot will be used to investigate (at least 10 studies contributed to a pooled analysis), whether publication bias will be present in the studies included in the review [33].

**Discussion**

This systematic review and meta-analysis aim to provide and inform researchers and practitioners in the corresponding areas (clinicians and health regulators) of the evidence on preclinical research and relevant existing evidence regarding mushrooms and their relationship with body weight loss in animal models of obesity, being non-aquatic mammals. Also, this study aims to present the strengths and limitations of the studies available in the literature and offer future perspectives in this field.

Although many experimental studies on the effects of mushrooms on obesity have already been published, there is still no consensus in the literature. Therefore, a systematic analysis of existing experimental studies is necessary.

**Supplementary information**

Supplementary information accompanies this paper at https://doi.org/10.1186/s13643-019-1205-3.

**Additional file 1. Search Strategy for database.**

**Abbreviations**

95% CI: 95% confidence intervals; CAMARADES: Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies; MeSH: Medical Subject Headings; OR: Odds ratio; PRISMA-P: Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols; PROSPERO: International Prospective Register of Systematic Reviews; RR: Risk ratio; SMD: Standardized mean difference; SYRCLE: SYstematic Review Center for Laboratory animal Experimentation; WHO: World Health Organization

**Authors’ contributions**

DG is the project managers, contributed to the writing and revision of the protocol, and will participate in data extraction. IFC is one of the principal investigators, led the writing of the manuscript, and will participate in data extraction. LGM is responsible for search strategy and helped to draft the protocol. JC is a co-investigator, contributed in protocol registration, and will participate in data extraction. RALV is a co-investigator and helped and will participate in data extraction. CCB is co-investigator, contributed to the revision of the protocol and manuscript, and will participate in data extraction. LCL is the project managers, co-investigator, drafted the manuscript, and will do statistical analysis. All authors read and approved the final manuscript.

**Funding**

This project is funded by governmental Program Graduate Education Institutions—PROSUC—CAPES/UNISO.

**Availability of data and materials**

Not applicable.
References

1. WHO. Obesity: preventing and managing the global epidemic. WHO Technical Report Series number 916. Geneva: WHO; 2003.

2. Leslie WS, Hankey CR, Lean ME. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100(7):395–404.

3. WHO. Diet, nutrition and the prevention of chronic diseases: report of a Joint WHO/FAO Expert Consultation. WHO Technical Report Series number 916. Geneva: WHO; 2003.

4. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. Nutr Rev. 2012;70(1):3–21.

5. Gortmaker SL, Swinburn BA, Levy D, Carter R, Mabry PL, Finegood DT, et al. Changing the future of obesity: science, policy, and action. Lancet. 2011;378(9793):838–47.

6. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. Global, regional, and national trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557–67.

7. Park H-S, Cho J-H, Kim K-W, Chung W-S, Song M-Y. Effects of Panax ginseng on obesity in animal models: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2018;2018:16.

8. Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14(1):12–24.

9. Wilding JPH. Medication use for the treatment of diabetes in obese individuals. Diabetologia. 2018;61(2):265–72.

10. Roupas P, Keogh J, Noakes M, Margetts B, Taylor P. The role of edible mushrooms in health: evaluation of the evidence. J Funct Foods. 2012;4(4):687–709.

11. Manz P, Gambelli L, Marconi S, Vivanti V, Pizzoferrato L. Nutrients in edible mushrooms: an inter-species comparative study. Food Chem. 1999;65(4):687–92.

12. Větvička V, Horáček J, Valášek P, Švětliková M, Sávršenová J, Černý P, et al. Anticancer effects of fraction isolated from fruiting body of Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2015;6:7489.

13. Novak M, Vetvicka V. Nutrients in edible mushrooms: an inter-species comparative study. Food Chem. 1999;65(4):687–92.

14. Chen L, Zhang Y, Sha O, Xu W, Wang S. Hypolipidaemic and hypoglycaemic activities of polysaccharide from Pleurotus eryngii in Kunming mice. Int J Biol Macromol. 2016;93:1206–9.

15. Wu T, Xu B. Antidiabetic and antioxidant activities of eight medicinal mushroom species from China. Int J Med Mushrooms. 2015;17(2):129–40.

16. Chang CJ, Lin CS, Lu CC, Martel J, Ko YF, Ojcius DM, et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota. Nat Commun. 2015;6:7489.

17. Chang CJ, Lu CC, Lin CS, Martel J, Ko YF, Ojcius DM, et al. Antioxidant cinnamomea reduces obesity and modulates the gut microbiota in high-fat diet-fed mice. Int J Obes. 2018;42(2):231–43.

18. Shamsaei L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g3647.

19. Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW. Systematic review and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab. 2011;34(3):373–42.

20. Peters JL, Sutton AJ, Jones DR, Rushton L, Abrams KR. A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B. 2006;41(7):1245–58.

21. Hooijmans CR, Tillema A, Leenaars M, Ritsema-Hoitinga M. Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed. Lab Anim. 2010;44(3):170–5.

22. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritsema-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.

23. Wu T, Xu B. Antidiabetic and antioxidant activities of eight medicinal mushroom species from China. Int J Med Mushrooms. 2015;17(2):129–40.

24. Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW. Systematic review and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab. 2011;34(3):373–42.

25. Peters JL, Sutton AJ, Jones DR, Rushton L, Abrams KR. A systematic review of systematic reviews and meta-analyses of animal experiments with guidelines for reporting. J Environ Sci Health B. 2006;41(7):1245–58.

26. Hooijmans CR, Tillema A, Leenaars M, Ritsema-Hoitinga M. Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed. Lab Anim. 2010;44(3):170–5.

27. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritsema-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.

28. Sena ES, van der Worp HB, Howells D, Macleod M. How can we improve the preclinical development of drugs for stroke? Trends Neurosci. 2007;30(9):433–9.

29. Macleod MR, O’Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke. 2004;35(5):1203–8.

30. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7445):557–60.

31. Hooijmans CR, de Vries RBM, Ritsema-Hoitinga M, Rovers MM, Leeflang MMA, Inthout J, et al. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. PLoS One. 2018;13(1):e0187271.

32. Hooijmans C, van der Worp HB, Leenaars M, Ritsema-Hoitinga M, Langendam MW. SRUCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.

33. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected graphically. BMJ. 1997;315(7109):629–34.

34. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected graphically. BMJ. 1997;315(7109):629–34.

35. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected graphically. BMJ. 1997;315(7109):629–34.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.